Cargando…
Early cerebral hypoxia in extremely preterm infants and neurodevelopmental impairment at 2 year of age: A post hoc analysis of the SafeBoosC II trial
BACKGROUND: The SafeBoosC II, randomised clinical trial, showed that the burden of cerebral hypoxia was reduced with the combination of near infrared spectroscopy and a treatment guideline in extremely preterm infants during the first 72 hours after birth. We have previously reported that a high bur...
Autores principales: | Plomgaard, Anne Mette, Schwarz, Christoph E., Claris, Olivier, Dempsey, Eugene M., Fumagalli, Monica, Hyttel-Sorensen, Simon, Lemmers, Petra, Pellicer, Adelina, Pichler, Gerhard, Greisen, Gorm |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786171/ https://www.ncbi.nlm.nih.gov/pubmed/35073354 http://dx.doi.org/10.1371/journal.pone.0262640 |
Ejemplares similares
-
No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC II) in preterm infants during the first days of life
por: Plomgaard, Anne M., et al.
Publicado: (2018) -
The SafeBoosC phase II clinical trial: an analysis of the interventions related with the oximeter readings
por: Riera, Joan, et al.
Publicado: (2016) -
Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
por: Plomgaard, Anne M., et al.
Publicado: (2017) -
Brain injury in the international multicenter randomized SafeBoosC phase II feasibility trial: cranial ultrasound and magnetic resonance imaging assessments
por: Plomgaard, Anne M, et al.
Publicado: (2016) -
The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury
por: Plomgaard, Anne M., et al.
Publicado: (2016)